Three related articles in this issue addressing clinical and translational (C/T) research suggest four simple questions about such research that should be considered by policy makers at a national level, by academic institutions, and by individual scientists: What, who, how, and why. The author of this commentary posits that ambiguity in answering these questions means that policy makers are not providing a clear target for institutions and researchers.
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Three related articles in this issue addressing clinical and translational (C/T) research suggest four simple questions about such research that should be considered by policy makers at a national level, by academic institutions, and by individual scientists: What, who, how, and why. The author of this commentary posits that ambiguity in answering these questions means that policy makers are not providing a clear target for institutions and researchers. The vagueness of the definitions may also obscure accountability with regard to assessing whether the rhetoric matches actions-for instance, what is the distribution of research activities and funding across the different phases of C/T research? Given the rapid evolution of new tools and methodologies in C/T research, it is important to consider each of these issues across the full developmental pathway of a C/T researcher. Overcoming these challenges and rapidly advancing along the pathway of creating knowledge to enhance the health of our communities and the nation depends on coherence and agreement by all players involved in C/T policy, funding, and participation. 
AtthePassoverSeder,Jewishtradition
obligates all participants to ask and respond to four questions regarding the unique attributes of the holiday. Although typically recited by the youngest (and, thus, most naïve) child at the table, these questions are intended to be a focus of serious discussion and thought for the broader community, the family, and the individual because they represent important, larger issues.
In a similar manner, the articles in this issue relating to clinical and translational (C/T) research suggest four simple, yet profound questions regarding such research that should be considered by policy makers at a national level, by academic institutions, and by individual scientists: What, who, how, and why. mentorship. However, given the rapid evolution of new tools and methodologies in C/T research, it is important to consider each of these issues across the full developmental pathway of a C/T researcher-that is, from undergraduate experience (or, perhaps, even birth) to retirement.
Moreover, as Heller and de Melo-Martín note, academic rewards and incentives are generally not under the control of CTSAs but require leadership and action at higher institutional levels. In a recent article, Keyser et al 6 suggest how such leadership can be exercised and assessed with regard to research mentorship. In addition, just as a clearer notion of the "what" is needed, there also should be a clear set of expectations for the "who." An overarching description of the roles/ tasks of a C/T researcher, adapted from an article by Burke et al, 7 is suggested in List 1, and a more detailed set of C/T research competencies is being developed by the CTSA Consortium Education Committee.
How are we going to overcome these challenges and rapidly advance along the pathway of creating knowledge to enhance the health of our communities and the nation? Obviously, answering this third question is beyond the space and scope of this commentary. Nonetheless, it is worth noting some of the multiple "subquestions" that are embedded in this complex question: Where should C/T research activities take place? (It can't be just the CTSAs.) How can the practical and regulatory barriers be overcome (and still maintain oversight, accountability, and adherence to the highest ethical standards)? How much funding will be needed (and where will it come from)? How can we best evaluate these strategies (and change them if expectations are not being met)?
There is, finally, the fourth question: Why is this research different from all other research? The answer is simple and, perhaps, can be summed up by paraphrasing Bill Clinton's Presidential Campaign War Room: "It's the patient, stupid!"
